Publications by authors named "Laura Bourillon"
Article Synopsis
- - Personalized cancer treatments have become essential in oncology, leading to better outcomes but also increasing the focus on long-term side effects for survivors, with 5-10% facing severe late toxicity from radiotherapy.
- - The identification of patients at risk for severe side effects before treatment can allow adjustments in their care to enhance their quality of life, for which various tests and biomarkers have been created over the years.
- - Among these tests, the Radiation-Induced Lymphocyte Apoptosis (RILA) assay has been the only one prospectively validated on a large scale and shows promise in predicting late radiation-induced toxicity across multiple cancer types, aiding decision-making in precision radiation oncology.
Purpose: The outcome of locally advanced cervical cancer (LACC) is dismal. Biomarkers are needed to individualize treatments and to improve patient outcomes. Here, we investigated whether coexpression of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) could be an outcome prognostic biomarker, and whether targeting both EGFR and HER3 with a dual antibody (MEHD7945A) enhanced ionizing radiation (IR) efficacy.
View Article and Find Full Text PDFPancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by poor response to chemotherapy and radiotherapy due to the lack of efficient therapeutic tools and early diagnostic markers. We previously generated the nonligand competing anti-HER3 antibody 9F7-F11 that binds to pancreatic tumor cells and induces tumor regression in vivo in experimental models. Here, we asked whether coupling 9F7-F11 with a radiosensitizer, such as monomethylauristatin E (MMAE), by using the antibody-drug conjugate (ADC) technology could improve radiation therapy efficacy in PDAC.
View Article and Find Full Text PDF